Earlier detection only matters if people can access it.
At AIRA Sciences, we believe multi-cancer screening and detection should be accurate, non-invasive, simple, accessible and affordable.
So, people can live life fully.
We know earlier detection can improve outcomes.
AIR-DS Lung Test
A simple cheek swab.
Intended for use within existing clinical workflows and sites of care
Does not require blood
Does not require temperature-controlled specimen handling
Does not require specialized collection equipment
The problem we are solving
Often cancer is found at late stages.
Failure of widespread screening is the result of many implementation gaps and innovative technology.
01
Awareness
A patient has to know the risk applies to them, and act on it.
02
Access
Reaching a service depends on cost, distance and time away from work.
03
Navigation
Referrals, appointments, follow-up and results must be coordinated across the pathway.
04
Affordability
A price point that allows widespread use.
This is what AIRA Sciences is purposefully designing for — A simple test that is accessible and affordable, meeting patients where they already are.
Why earlier detection matters
Stage at diagnosis can fundamentally change what follows.
Survival
Lung cancer outcomes differ substantially by stage at diagnosis.1
Time
It is reported the average time between first symptom and diagnosis is 570 days in the U.S.2
Translation
Research has estimated an average lag of approximately 17 years between evidence and widespread practice.3
References
Goldstraw, P., et al. (2016). The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. Journal of Thoracic Oncology, 11(1), 39–51.
Suchsland, M. Z., et al. (2022). How Timely Is Diagnosis of Lung Cancer? Cohort Study of Individuals with Lung Cancer Presenting in Ambulatory Care in the United States. Cancers (Basel), 14(23), 5756.
Morris, Z. S., Wooding, S., & Grant, J. (2011). The answer is 17 years, what is the question: understanding time lags in translational research. Journal of the Royal Society of Medicine, 104(12), 510–520.
Stories
We are listening to the people who have lived this journey.
Patients, families and clinicians on what timing, access and navigating cancer care actually involved for them.
Advancing infrared applications for earlier detection — beginning with lung cancer.
AIR-DS is a UKCA marked in vitro diagnostic medical device, developed in accordance with IEC 62304 and under an ISO 13485 certified quality management system. In the US, a CLIA certified laboratory will offer a laboratory developed test (LDT) with AIR-DS Lung Test. It has not been cleared or approved by the FDA. Information on this website is provided for educational and informational purposes and should not be interpreted as medical advice.